Patent application number | Description | Published |
20090130115 | ANTIBODIES RECOGNIZING A HIGHLY EXPRESSED PUTATIVE ANTIGEN OF CA-MRSA AND METHODS OF USE - The present invention provides MSCRAMM® proteins from | 05-21-2009 |
20090162379 | Inhibitors of S. aureus SdrD protein attachment to cells and uses therefor - Provided herein is a method for identifying small molecule inhibitors of | 06-25-2009 |
20090170751 | Formation of superfibronectin by BBK32 and uses therefor - Provided herein is a method for inducing formation of a conformationally distinct superfibronectin by contacting plasma fibronectin with BBK32 protein or a BBK32 peptide and the BBK32-induced superfibronectin so formed. Also provided are methods of inhibiting endothelial cell proliferation, of treating pathophysiological conditions associated with endothelial cell proliferation and of inhibiting angiogenesis therein using the BBK32 protein, BBK32 peptide or the BBK32-induced superfibronectin. | 07-02-2009 |
20090203627 | Specific binding sites in collagen for integrins and use thereof - The present invention identified a high affinity binding sequence in collagen type III for the collagen-binding integrin I domains. Provided herein are the methods used to characterize the sequence, the peptides comprising this novel sequence and the use of the peptides in enabling cell adhesion. Also provided herein are methods to identify specific integrin inhibitors, sequences of these inhibitors and their use in inhibiting pathophysiological conditions that may arise due to integrin-collagen interaction. | 08-13-2009 |
20090258390 | Prokaryotic collagen-like proteins and uses thereof - The present invention provides recombinant triple helical proteins or collagen-like proteins comprising a prokaryotic protein or one or more domains of a prokaryotic protein comprising a collagen-like peptide sequence of repeated Gly-Xaa-Yaa triplets and, optionally, one or more domains from a mammalian collagen. Also provided are expression vectors and host cells containing the expression vectors to produce these recombinant proteins and methods of producing the same. Additionally, antibodies are provided that are directed against a recombinant collagen-like protein that, preferably, binds an integrin. Furthermore, a method of screening for potential therapeutic compounds that inhibit the integrin-binding or integrin-interacting activities of recombinant collagen-like proteins. | 10-15-2009 |
20100015138 | Crystal structure of Staphylococcus aureus clumping factor a in complex with fibrinogen derived peptide and uses thereof - The present invention discloses crystal structure of | 01-21-2010 |
20100068220 | BIOINFORMATIC METHOD FOR IDENTIFYING SURFACE-ANCHORED PROTEINS FROM GRAM-POSITIVE BACTERIA AND PROTEINS OBTAINED THEREBY - A bioinformatic method for identifying and isolating proteins and peptides with MSCRAMM®-like characteristics from Gram positive bacteria, such as | 03-18-2010 |
20100150956 | MULTICOMPONENT VACCINES - Multicomponent vaccines are provided which aid in the prevention and treatment of staphylococcal infections and which include certain selected combinations of bacterial binding proteins or fragments thereof, or antibodies to those proteins or fragments. By careful selection of the proteins, fragments, or antibodies, a vaccine is provided that imparts protection against a broad spectrum of | 06-17-2010 |
20100183623 | MONOCLONAL ANTIBODIES RECOGNIZING A COAGULASE-NEGATIVE STAPHYLOCOCCAL PROTEIN - Monoclonal antibodies which can bind to the SdrF protein of | 07-22-2010 |
20100184085 | Prokaryotic collage-like proteins and uses thereof - The present invention provides recombinant triple helical proteins or collagen-like proteins comprising a prokaryotic protein or one or more domains of a prokaryotic protein comprising a collagen-like peptide sequence of repeated Gly-Xaa-Yaa triplets and, optionally, one or more domains from a mammalian collagen. Also provided are expression vectors and host cells containing the expression vectors to produce these recombinant proteins and methods of producing the same. Additionally, antibodies are provided that are directed against a recombinant collagen-like protein that, preferably, binds an integrin. Furthermore, a method of screening for potential therapeutic compounds that inhibit the integrin-binding or integrin-interacting activities of recombinant collagen-like proteins. | 07-22-2010 |
20110171285 | Design of Fibrinogen and Fibrinogen Derived Products with Reduced Bacterial Binding by Using Modified Sequences of Fibrinogen Chains - The present invention describes the design and development of new fibrinogen and fibrinogen derived products with significantly reduced binding to bacteria while retaining normal physiological functions by using modified fibrinogen amino acid sequences. The present invention describes modified sequences of Fg γ-chains and β-chains with reduced binding to | 07-14-2011 |
20110288274 | Designer collagens and use thereof - The present invention identified a recombinant synthetic collagen containing a triple helical backbone protein produced in a prokaryotic expression system where the protein contains at least one ‘inserted’ biologically active sequence(s). | 11-24-2011 |
20130035476 | CRYSTAL STRUCTURE OF STAPHYLOCOCCUS AUREUS CLUMPING FACTOR A IN COMPLEX WITH FIBRINOGEN DERIVED PEPTIDE AND USES THEREOF - The present invention discloses crystal structure of | 02-07-2013 |
20130150300 | SPECIFIC BINDING SITES IN COLLAGEN FOR INTEGRINS AND USE THEREOF - The present invention identified a high affinity binding sequence in collagen type III for the collagen-binding integrin I domains. Provided herein are the methods used to characterize the sequence, the peptides comprising this novel sequence and the use of the peptides in enabling cell adhesion. Also provided herein are methods to identify specific integrin inhibitors, sequences of these inhibitors and their use in inhibiting pathophysiological conditions that may arise due to integrin-collagen interaction. | 06-13-2013 |
20140163205 | DESIGNER COLLAGENS AND USE THEREOF - The present disclosure provides synthetic collagen and methods of making and using synthetic collagen that include a synthetic collagen that facilitates wound closure comprising an isolated and purified triple helical backbone protein that facilitates wound closure comprising one or more alteration in a triple helical backbone protein sequence, that stabilize the isolated and purified triple helical backbone protein and does not disrupt an additional collagen ligand interaction; and one or more integrin binding motifs, wherein the isolated and purified triple helical backbone protein facilitates wound closure. | 06-12-2014 |